#GU15 - Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients - Session Highlights

ORLANDO, FL, USA (UroToday.com) - Cell cycle progression (CCP) is a validated genetic assay that assesses risk of individual prostate cancer progression and disease-specific mortality when combined with clinicopathologic parameters. PROCEDE-1000 is the largest prospective registry that was created to evaluate CCP test impact on personalizing prostate cancer treatment.

gucancerssympaltUntreated patients with newly diagnosed (< 6 months) localized prostate adenocarcinoma (n = 816) were enrolled. The physicians’ initial therapy recommendation (Pre-CCP) was recorded on the first questionnaire, based on biopsy data. Subsequently, CCP test was conducted on prostate biopsy tissue. Three post-CCP questionnaires recorded the physicians’ revised treatment recommendation, physician/patient treatment decision, and final treatment administered. Changes in treatments between the pre-CCP and post-CCP questionnaires were assessed to determine the impact of CCP testing.

Visual analog scale measurements indicated a significant increase in the physicians’ likelihood of recommending non-interventional treatment after CCP test. CCP score led to treatment change in 44% of patients, of whom 72% of changes were reductions in treatment. Reductions occurred across all treatment modalities—27% prostatectomy, radiation therapy (44% primary; 56% adjuvant), brachytherapy (46% interstitial; 66% HDR), and hormonal therapy (33% neoadjuvant; 68% concurrent). There was an increase in active surveillance from the initial interventional therapy. While 35.9% were recommended for conservative management pre-CCP, there was a 6.5% increase in non-interventional treatments during follow-up.

The group concluded that the CCP risk score has a significant impact in helping physicians and patients select a personalized treatment option.

Presented by Neal D. Shore, Judd Boczko, Naveen Kella, Brian Joseph Moran, E. David Crawford, Stephanie A. Hamilton, Rajesh R. Kaldate, Kirstin M Roundy, Michael K. Brawer, and Mark L. Gonzalgo at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA

Carolina Urologic Research Center, Myrtle Beach, SC; WESTMED Medical Group, White Plains, NY; The Urology and Prostate Institute, San Antonio, TX; Prostate Cancer Foundation of Chicago, Westmont, IL; University of Colorado Health Science Center, Aurora, CO; Myriad Genetic Laboratories, Inc., Salt Lake City, UT; University of Miami Miller School of Medicine, Miami, FL

Reported by Mohammed Haseebuddin, MD, medical writer for UroToday.com